Identification of Mycobacterium tuberculosis Resistance to Common Antibiotics: An Overview of Current Methods and Techniques
Xue-Song Xiong,Xue-Di Zhang,Jia-Wei Yan,Ting-Ting Huang,Zhan-Zhong Liu,Zheng-Kang Li,Liang Wang,Fen Li
DOI: https://doi.org/10.2147/idr.s457308
2024-04-12
Infection and Drug Resistance
Abstract:Xue-Song Xiong, 1, 2, &ast Xue-Di Zhang, 3, &ast Jia-Wei Yan, 3 Ting-Ting Huang, 1, 2 Zhan-Zhong Liu, 4 Zheng-Kang Li, 5 Liang Wang, 5 Fen Li 1, 2 1 Department of Laboratory Medicine, The Affiliated Huai'an Hospital of Yangzhou University, Huai'an, Jiangsu Province, People's Republic of China; 2 Department of Laboratory Medicine, The Fifth People's Hospital of Huai'an, Huai'an, Jiangsu Province, People's Republic of China; 3 Department of Laboratory Medicine, Xuzhou Infectious Diseases Hospital, Xuzhou, Jiangsu Province, People's Republic of China; 4 Department of Pharmacy, Xuzhou Infectious Diseases Hospital, Xuzhou, Jiangsu Province, People's Republic of China; 5 Department of Laboratory Medicine, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou, Guangdong Province, People's Republic of China &astThese authors contributed equally to this work Correspondence: Liang Wang; Fen Li, Email ; Multidrug-resistant tuberculosis (MDR-TB) is an essential cause of tuberculosis treatment failure and death of tuberculosis patients. The rapid and reliable profiling of Mycobacterium tuberculosis (MTB) drug resistance in the early stage is a critical research area for public health. Then, most traditional approaches for detecting MTB are time-consuming and costly, leading to the inappropriate therapeutic schedule resting on the ambiguous information of MTB drug resistance, increasing patient economic burden, morbidity, and mortality. Therefore, novel diagnosis methods are frequently required to meet the emerging challenges of MTB drug resistance distinguish. Considering the difficulty in treating MDR-TB, it is urgently required for the development of rapid and accurate methods in the identification of drug resistance profiles of MTB in clinical diagnosis. This review discussed recent advances in MTB drug resistance detection, focusing on developing emerging approaches and their applications in tangled clinical situations. In particular, a brief overview of antibiotic resistance to MTB was present, referred to as intrinsic bacterial resistance, consisting of cell wall barriers and efflux pumping action and acquired resistance caused by genetic mutations. Then, different drug susceptibility test (DST) methods were described, including phenotype DST, genotype DST and novel DST methods. The phenotype DST includes nitrate reductase assay, Roche TM solid ratio method, and liquid culture method and genotype DST includes fluorescent PCR, GeneXpert, PCR reverse dot hybridization, ddPCR, next-generation sequencing and gene chips. Then, novel DST methods were described, including metabolism testing, cell-free DNA probe, CRISPR assay, and spectral analysis technique. The limitations, challenges, and perspectives of different techniques for drug resistance are also discussed. These methods significantly improve the detection sensitivity and accuracy of multidrug-resistant tuberculosis (MRT) and can effectively curb the incidence of drug-resistant tuberculosis and accelerate the process of tuberculosis eradication. Keywords: MTB, antibiotic resistance, Raman spectroscopy, rapid detection Graphical Just as the 2023 global tuberculosis report released by the World Health Organization (WHO), 7.5 million tuberculosis patients were newly diagnosed globally in 2022, with an estimated 1.3 million deaths, nearly twice the rate of HIV/AIDS. At present, tuberculosis, a class A infectious disease aroused by Mycobacterium tuberculosis (MTB), has turned into the first cause of death of a single infectious disease after novel coronavirus pneumonia. Although the clinical detection rate of MTB has increased, over 90% of the pathogenic bacteria of human pulmonary tuberculosis are MTB. Its main transmission routes are air and contact, and it is easy to form an explosive epidemic. The main high-risk places include schools, nursing homes, and other vital social places, which cause potential significant harm to public security. The treatment cycle of tuberculosis and multidrug-resistant tuberculosis is time-losing and expensive, resulting in a substantial social and economic burden on countries and individual patients. 1 Then, the incidence data of multidrug-resistant tuberculosis (MRT) and rifampicin-resistant tuberculosis in China is the fourth in the world, and China is one of the high-burden countries with drug-resistant tuberculosis in the world. So, timely and effective identification of MTB infection diagnosis and its drug resistance can effectively realize the early detection, early control, and precise treatment of tu -Abstract Truncated-
pharmacology & pharmacy,infectious diseases